Signal Genetics Company Profile (NASDAQ:MGEN)

About Signal Genetics (NASDAQ:MGEN)

Signal Genetics logoSignal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company's diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual's long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company's MyPRS test provides a whole-genomic expression profile of a patient's multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MGEN
  • CUSIP: N/A
  • Web:
  • Market Cap: $313.1 million
  • Outstanding Shares: 21,407,000
Average Prices:
  • 50 Day Moving Avg: $11.72
  • 200 Day Moving Avg: $11.82
  • 52 Week Range: $1.80 - $18.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.97
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.02 million
  • Price / Sales: 103.70
  • Book Value: $2.24 per share
  • Price / Book: 6.53
  • EBIDTA: ($20,050,000.00)
  • Net Margins: -555.68%
  • Return on Equity: -109.13%
  • Return on Assets: -81.59%
  • Debt-to-Equity Ratio: 0.05%
  • Current Ratio: 7.83%
  • Quick Ratio: 7.83%
  • Average Volume: 61,424 shs.
  • Beta: 1.88
  • Short Ratio: 5.26
Frequently Asked Questions for Signal Genetics (NASDAQ:MGEN)

What is Signal Genetics' stock symbol?

Signal Genetics trades on the NASDAQ under the ticker symbol "MGEN."

How were Signal Genetics' earnings last quarter?

Signal Genetics, Inc. (NASDAQ:MGEN) issued its earnings results on Wednesday, May, 10th. The company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.36. The company earned $0.46 million during the quarter, compared to analyst estimates of $1 million. Signal Genetics had a negative return on equity of 109.13% and a negative net margin of 555.68%. View Signal Genetics' Earnings History.

Where is Signal Genetics' stock going? Where will Signal Genetics' stock price be in 2017?

3 equities research analysts have issued 1-year price targets for Signal Genetics' shares. Their predictions range from $4.00 to $17.00. On average, they anticipate Signal Genetics' stock price to reach $10.50 in the next year. View Analyst Ratings for Signal Genetics.

Who are some of Signal Genetics' key competitors?

How do I buy Signal Genetics stock?

Shares of Signal Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Signal Genetics' stock price today?

One share of Signal Genetics stock can currently be purchased for approximately $14.63.

MarketBeat Community Rating for Signal Genetics (NASDAQ MGEN)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about Signal Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Signal Genetics (NASDAQ:MGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.50 (28.23% downside)

Analysts' Ratings History for Signal Genetics (NASDAQ:MGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/1/2017Cowen and CompanyInitiated CoverageOutperformMediumView Rating Details
5/11/2017WedbushBoost Price TargetOutperform$16.00 -> $17.00LowView Rating Details
8/21/2016Rodman & RenshawSet Price TargetBuy$4.00N/AView Rating Details
1/26/2016AegisReiterated RatingBuyN/AView Rating Details
1/8/2016HC WainwrightInitiated CoverageBuy$4.00N/AView Rating Details
9/23/2015Chardan CapitalReiterated RatingBuy$2.75N/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Signal Genetics (NASDAQ:MGEN)
Earnings by Quarter for Signal Genetics (NASDAQ:MGEN)
Earnings History by Quarter for Signal Genetics (NASDAQ MGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.24)($0.60)$1.00 million$0.46 millionViewN/AView Earnings Details
5/16/2016Q116($0.28)($0.26)$645.00 million$808.00 millionViewN/AView Earnings Details
3/16/2016Q415($0.36)($0.28)$0.60 million$0.66 millionViewN/AView Earnings Details
8/12/2015Q215($0.39)($0.33)$0.73 millionViewN/AView Earnings Details
5/14/2015Q115($0.36)($0.45)$1.90 million$0.65 millionViewN/AView Earnings Details
3/30/2015($0.39)($1.72)ViewN/AView Earnings Details
11/14/2014Q3 2014($0.05)($0.43)$1.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Signal Genetics (NASDAQ:MGEN)
2017 EPS Consensus Estimate: ($1.16)
2018 EPS Consensus Estimate: ($1.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.24)($0.24)($0.24)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.31)($0.31)($0.31)
Q4 20171($0.32)($0.32)($0.32)
Q1 20181($0.34)($0.34)($0.34)
Q2 20181($0.35)($0.35)($0.35)
Q3 20181($0.37)($0.37)($0.37)
Q4 20181($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)


Dividend History for Signal Genetics (NASDAQ:MGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Signal Genetics (NASDAQ:MGEN)
Insider Ownership Percentage: 44.40%
Institutional Ownership Percentage: 16.35%
Insider Trades by Quarter for Signal Genetics (NASDAQ:MGEN)
Institutional Ownership by Quarter for Signal Genetics (NASDAQ:MGEN)
Insider Trades by Quarter for Signal Genetics (NASDAQ:MGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/22/2017Adam Scott LevyInsiderBuy200$7.55$1,510.00View SEC Filing  
3/10/2017Kyle LefkoffDirectorSell5,800$14.34$83,172.00View SEC Filing  
3/8/2017Kyle LefkoffDirectorSell15,000$15.40$231,000.00View SEC Filing  
2/28/2017Kyle LefkoffDirectorSell10,258$13.89$142,483.62View SEC Filing  
2/23/2017Kyle LefkoffDirectorSell5,902$14.14$83,454.28View SEC Filing  
11/20/2015Samuel D. RiccitelliCEOBuy14,000$0.79$11,060.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Signal Genetics (NASDAQ:MGEN)
Latest Headlines for Signal Genetics (NASDAQ:MGEN)
DateHeadline logomiRagen Therapeutics, Inc. (Nasdaq: MGEN) to Ring The Nasdaq Stock Market Closing Bell - July 22 at 6:26 AM logoComparing BG Medicine (BGMD) and Signal Genetics (MGEN) - July 21 at 2:26 PM logoBG Medicine (BGMD) versus Signal Genetics (MGEN) Head-To-Head Review - July 21 at 2:24 PM logoZacks Investment Research Upgrades Signal Genetics, Inc. (NASDAQ:MGEN) to "Hold" - July 12 at 7:54 AM logo Signal Genetics, Inc. (MGEN) Given $26.37 Average Target Price by Brokerages - June 27 at 10:56 AM logoShould You Get Rid of Miragen Therapeutics (MGEN) Now? - June 9 at 6:43 PM logoMiragen Therapeutics (MGEN) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 8 at 10:23 AM logomiRagen Therapeutics to Present MRG-106 Phase 1 Clinical Trial Data at the International Conference on Malignant Lymphoma - June 8 at 10:23 AM logomiRagen Therapeutics Presents New Data from Phase 1 Clinical Trial Evaluating MRG-106 in Subjects with Mycosis Fungoides - June 5 at 9:21 AM logoMiragen Therapeutics, Inc. (MGEN) Upgraded at Zacks Investment Research - June 3 at 7:18 AM logoMiragen Therapeutics, Inc. (MGEN) Earns Outperform Rating from Analysts at Cowen and Company - June 1 at 10:00 AM logomiRagen Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference - June 1 at 9:25 AM logoMiragen Therapeutics (MGEN) Presents At UBS Global Healthcare Conference 2017 - Slideshow - May 24 at 10:44 AM logomiRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma - May 24 at 10:44 AM logomiRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, at the American Society of Clinical Oncology Annual Meeting - May 17 at 6:29 PM logoMiragen Therapeutics, Inc. (MGEN) Downgraded by Zacks Investment Research - May 16 at 7:36 AM logoQ2 2017 Earnings Forecast for Miragen Therapeutics, Inc. (MGEN) Issued By Wedbush - May 15 at 7:46 AM logoMiragen Therapeutics, Inc. (MGEN) Forecasted to Earn Q1 2018 Earnings of ($0.34) Per Share - May 12 at 4:08 PM logoMiragen Therapeutics, Inc. (MGEN) Posts Quarterly Earnings Results - May 11 at 7:18 PM logoMiragen Therapeutics' (MGEN) Outperform Rating Reiterated at Wedbush - May 11 at 5:24 PM logomiRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update - May 10 at 6:37 PM logoServier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics - May 3 at 8:11 PM logomiRagen Therapeutics to Host Conference Call Discussing First Quarter 2017 Corporate Update and Financial Results - May 2 at 4:39 PM logomiRagen Therapeutics (MGEN) Presents Interim Results from MRG-201 Phase 1 Clinical Trial - April 27 at 7:05 PM logomiRagen Therapeutics Presents Interim Results from MRG-201 Phase 1 Clinical Trial Demonstrating Pharmacodynamic Activity in Human Skin Incisions - April 27 at 7:05 PM logomiRagen Therapeutics to Participate in Two Investor Conferences in May - April 26 at 6:47 PM logoBrokerages Expect Miragen Therapeutics, Inc. (MGEN) to Announce ($0.24) EPS - April 26 at 9:30 AM logomiRagen Therapeutics to Present MRG-201 Data at the Society for Investigative Dermatology Annual Meeting - April 20 at 10:06 AM logo4:15 pm Miragen Therapeutics reported recent clinical and financial highlights along with anticipated milestones for 2017 - April 4 at 3:51 AM logoAnalysts Expect Miragen Therapeutics, Inc. (MGEN) to Post ($0.23) Earnings Per Share - April 3 at 11:37 PM logoMiragen Therapeutics, Inc. (MGEN) Rating Reiterated by Wedbush - April 3 at 2:34 PM logomiRagen Therapeutics Provides Corporate Update - March 31 at 6:38 PM logoMIRAGEN THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits - March 31 at 6:38 PM logomiRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides - March 31 at 9:39 AM logo7:04 am Miragen Therapeutics announces that the FDA has granted orphan-drug designation to miRagen's product candidate, MRG-106, for the treatment of mycosis fungoides - March 31 at 9:39 AM logoMIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Change in Directors or - March 30 at 6:49 PM logomiRagen Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference - March 28 at 10:28 AM logoWedbush Initiates Coverage on Miragen Therapeutics, Inc. (MGEN) - March 26 at 11:49 AM logoMIRAGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report - March 24 at 6:33 PM logoKyle Lefkoff Sells 15,000 Shares of Miragen Therapeutics, Inc. (MGEN) Stock - March 8 at 10:04 PM logoMiragen Therapeutics (MGEN) Presents At Cowen and Company 37th Annual Health Care Conference - March 8 at 7:17 PM logomiRagen Therapeutics to Participate in Two Investor Conferences in March - February 28 at 10:05 AM logoCoverage initiated on Miragen Therapeutics by Wedbush - February 21 at 6:22 PM logoWhy miRagen Therapeutics Shares Could See 60% Upside By 2018 - February 21 at 6:22 PM logoMIRAGEN THERAPEUTICS, INC. Financials - February 17 at 5:23 PM



Signal Genetics (MGEN) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by Staff